12:00 AM
Aug 31, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xyzal Levocetirizine regulatory update

FDA approved an sNDA from UCB for Xyzal levocetirizine to treat perennial allergic rhinitis and chronic idiopathic urticaria in patients ages >=6 months and to treat seasonal allergic rhinitis in patients ages >=2 years. UCB already...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >